Omalizumab as add‐on therapy in a patient with severe asthma and OSA

Obstructive sleep apnoea (OSA) syndrome, the most frequent sleep‐disordered breathing, is a comorbidity of asthma, whose prevalence covers about 49.5% of asthmatic adult patients. A 61‐year‐old female patient, affected by severe allergic asthma and obesity, started treatment with omalizumab and unde...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Respirol Case Rep
Egile Nagusiak: Scioscia, Giulia, Buonamico, Enrico, Foschino Barbaro, Maria Pia, Lacedonia, Donato, Sabato, Roberto, Carpagnano, Giovanna Elisiana
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley & Sons, Ltd 2020
Gaiak:
Case Reports
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7006716/
https://ncbi.nlm.nih.gov/pubmed/32055401
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/rcr2.518
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak